Maxime Culot

Maxime Culot is a Professor at the Faculty of Sciences, University of Artois in Lens, France. He earned his Ph.D. at the same institution in 2007 and has since specialized in pharmaceutical and toxicological applications of cell and tissue culture. His research focuses on studying xenobiotics transport across biological barriers using human stem cell-derived in vitro models, particularly the blood-brain barrier (BBB). He has contributed to developing innovative BBB models for drug screening and collaborated with pharmaceutical companies and organizations like AstraZeneca.

Dr. Culot coordinates the Master Tox & Ecotox program (MENACE), emphasizing New Approach Methodologies (NAMs) for toxicity assessment. He has led or participated in EU-funded projects, including FP7 Predict iv, H2020-ITN BtRAIN, and others, advancing in vitro toxicology and BBB modeling. His work integrates proteomics, cellular models, and computational tools to address neurovascular protection, drug permeability, and adverse outcome pathways. Culot’s lab develops strategies for predicting human neurotoxicity, improving drug delivery systems, and enhancing in vitro-to-in vivo extrapolation methods.

His research spans interdisciplinary topics such as stem cell-derived BBB models, extracellular vesicle standardization (MISEV guidelines), and the impact of differentiation protocols on transcriptomic signatures. He also investigates challenges in oral biologic delivery and the application of NAMs to reduce animal testing reliance. Culot’s contributions bridge basic science and translational research, with a focus on advancing safer and more effective pharmaceutical and toxicological practices.